HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.

AbstractBACKGROUND:
We previously reported that stage 3 neuroblastoma comprises (i) a low-risk group including all infants (age 0-11 months) as well as older children with non-abdominal primaries, and (ii) a high-risk group made up of children >1 year of age with abdominal primaries. Aggressive chemotherapy was effective only in the latter group.
PATIENTS AND TREATMENT:
On this basis, in 1990 we designed a new protocol by which all low-risk patients received standard-dose chemotherapy, while the high-risk ones received very aggressive chemotherapy.
RESULTS:
Between November 1990 and December 1997 a total of 95 eligible and evaluable children were enrolled: 47 were low-risk (35 infants and 12>1 year of age at diagnosis and having non-abdominal primaries), and 48 were high-risk (being >1 year of age and having abdominal primaries). Of the 47 low-risk patients, five relapsed and four subsequently died. The 5-year overall survival (OS) was 91%. Of the 48 patients in the high-risk group, 22 relapsed or progressed, 18 of whom died from their disease and two from toxicity, and one was lost to follow-up. The 5-year OS was 60%. Univariate analysis showed that age, site of primary, risk-group, urine vanillylmandelic excretion, plasma levels of lactate dehydrogenase, ferritin and neurone-specific enolase, and MYCN status correlated with outcome. However, multivariate analysis showed that only MYCN status retained prognostic value.
CONCLUSIONS:
In low-risk stage 3 neuroblastoma, standard-dose chemotherapy is associated with an excellent chance of being cured. Aggressive chemotherapy is effective for high-risk patients, but results are still unsatisfactory. MYCN gene amplification is a prognostic indicator for most, but not all, treatment failures.
AuthorsA Garaventa, L Boni, M S Lo Piccolo, G P Tonini, C Gambini, A Mancini, L Tonegatti, M Carli, L C di Montezemolo, A Di Cataldo, F Casale, K Mazzocco, G Cecchetto, A Rizzo, B Bernardi,
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO (Ann Oncol) Vol. 13 Issue 6 Pg. 956-64 (Jun 2002) ISSN: 0923-7534 [Print] England
PMID12123342 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
Topics
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Biopsy, Needle
  • Child
  • Child, Preschool
  • Cyclophosphamide (administration & dosage)
  • Dose-Response Relationship, Drug
  • Doxorubicin (administration & dosage)
  • Drug Administration Schedule
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Neuroblastoma (drug therapy, mortality, pathology, surgery)
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: